Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States - PubMed
10 hours ago
- #clinical trial
- #multiple myeloma
- #bispecific antibody
- Linvoseltamab (BCMA×CD3 bispecific antibody) was evaluated in the LINKER-MM1 Phase 1/2 study for triple-class-exposed or triple-class-refractory relapsed/refractory multiple myeloma.
- A comparison was made between the Phase 2 linvoseltamab 200 mg cohort (105 patients) and an external control arm of 149 real-world standard-of-care patients from US databases.
- Inverse probability of treatment weighting balanced baseline characteristics between cohorts.
- Real-world standard-of-care commonly included combinations like carfilzomib, pomalidomide, dexamethasone and daratumumab, pomalidomide, dexamethasone, with no CAR-T or bispecific antibody treatments.
- Linvoseltamab showed superior outcomes: higher objective response rate (weighted odds ratio 3.8), longer median progression-free survival (weighted HR 0.29), time to next treatment (weighted HR 0.20), and overall survival (weighted HR 0.41).